Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This medication helps improve lung function and oxygenation, often administered via endotracheal tube.

Curosurf is primarily used to manage respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed, leading to difficulty in breathing. The surfactant in Curosurf helps to reduce surface tension in the lungs, allowing them to expand more easily. It is often administered shortly after birth to support breathing and improve oxygen levels.

Curosurf works by coating the inner surface of the lungs, reducing the surface tension that can cause the air sacs to collapse. This helps to improve lung compliance and gas exchange, making it easier for the infant to breathe. The effects are typically observed soon after administration, providing immediate support to the respiratory system.

Curosurf should be administered by healthcare professionals experienced in neonatal intensive care. It is important to monitor the infant closely for any signs of adverse reactions. The medication should be stored and handled according to the manufacturer's guidelines to ensure its effectiveness and safety.

Curosurf is generally used in a controlled medical environment, and interactions with other medications are not commonly reported. However, it is important to inform the healthcare provider about any other medications the infant may be receiving to avoid potential complications.